Compare NPV & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPV | SLN |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 236.2M |
| IPO Year | N/A | N/A |
| Metric | NPV | SLN |
|---|---|---|
| Price | $11.73 | $5.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 38.0K | ★ 185.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.68 | $1.97 |
| 52 Week High | $12.50 | $7.78 |
| Indicator | NPV | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 67.35 | 48.57 |
| Support Level | $11.36 | $5.17 |
| Resistance Level | N/A | $6.10 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 70.42 | 37.88 |
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.